Effects of Feeding Oxalic Acid to Pregnant Rats

Two studies were carried out. The aim of the pilot study was to find a suitable dose ofoxalic acid to be used in the principal study. Thirty pregnant Wister rats were used in the p'rincipal study divided into three groups of 10 animals each. The animals in two groups received oxalic acid at 0.035 g and 0.045 g per day per animal until parturition. The animals in the third group received normal saline. No abortions, gross malformations or renal oxalosis were observed in the foetuses and newborn in both studies. However changes comparable to tubulonephrosis were observed in the newborn in the group receiving 0.03 gf day in the pilot study. A correlation was observed in the principal study between the dose of oxalic acid and renal oxalosis in the dams as well as differences in litter size. Possible reasons for these observations were discusse

Customer Communication of Regional Quality Efforts: A Case From the Grain Sector

Usually, marketing communication efforts in the agrifood sector address the end consumers and concentrate on products that are processed and ready for consumption, thus quality efforts often concentrate on the final product. Moreover, there’s a widespread view that agricultural commodities like wheat aren’t suitable neither for product focused marketing nor branding. However, recent developments in the in agrifood sector challenge this view. The increasing use of biotechnology, the globalisation of markets and changing consumer demands for quality, food safety and process attributes require improved communication concepts and information sharing along whole production chains. This paper considers the development of a quality communication system to support a regional wheat brand and prerequisites for quality management efforts

Moving Forward: Advances in the Treatment of Movement Disorders with Deep Brain Stimulation

The modern era of stereotactic and functional neurosurgery has ushered in state of the art technologies for the treatment of movement disorders, particularly Parkinson’s disease (PD), tremor, and dystonia. After years of experience with various surgical therapies, the eventual shortcomings of both medical and surgical treatments, and several serendipitous discoveries, deep brain stimulation (DBS) has risen to the forefront as a highly effective, safe, and reversible treatment for these conditions. Idiopathic advanced PD can be treated with thalamic, globus pallidus internus (GPi), or subthalamic nucleus (STN) DBS. Thalamic DBS primarily relieves tremor while GPi and STN DBS alleviate a wide range of Parkinsonian symptoms. Thalamic DBS is also used in the treatment of other types of tremor, particularly essential tremor, with excellent results. Both primary and various types of secondary dystonia can be treated very effectively with GPi DBS. The variety of anatomical targets for these movement disorders is indicative of the network-level dysfunction mediating these movement disturbances. Despite an increasing understanding of the clinical benefits of DBS, little is known about how DBS can create such wide sweeping neuromodulatory effects. The key to improving this therapeutic modality and discovering new ways to treat these and other neurologic conditions lies in better understanding the intricacies of DBS. Here we review the history and pertinent clinical data for DBS treatment of PD, tremor, and dystonia. While multiple regions of the brain have been targeted for DBS in the treatment of these movement disorders, this review article focuses on those that are most commonly used in current clinical practice. Our search criteria for PubMed included combinations of the following terms: DBS, neuromodulation, movement disorders, PD, tremor, dystonia, and history. Dates were not restricted